Discovery of biaryls as RORγ inverse agonists by using structure-based design

Discovery of biaryls as RORγ inverse agonists by using structure-based design Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORγ inhibitors using virtual screening, synthesis and biological evaluation Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity Discovery of aryl-substituted indole and indoline derivatives as RORγt agonists Structure–activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand